#Israel #Caesarea #IceCure Medical #ProSense Cryoablation #THERMAC Trial

IceCure Medical's ProSense®: A Breakthrough in Breast Cancer Treatment

Recent publications from the THERMAC Trial, an independent study in the Netherlands, shine a spotlight on IceCure Medical's innovative ProSense® cryoablation technology for breast cancer treatment. With a remarkable 95% of patients expressing satisfaction with the thermal ablation procedure, these findings exemplify the efficacy and safety of this minimally invasive technique.

The THERMAC Trial Overview

The THERMAC Trial, which set out to compare various thermal ablation techniques, concluded that ProSense® provides superior cosmetic outcomes compared to traditional surgery for early-stage breast cancer patients. Led by Dr. Sophie Wooldrik from the Department of Surgery at Franciscus Gasthuis Vlietland in Rotterdam, the trial included 41 patients who underwent different methods of thermal ablation.

Dr. Eyal Shamir, CEO of IceCure Medical, hailed these peer-reviewed publications as pivotal for further validating the clinical benefits of ProSense®. He emphasized that the results demonstrate not only the safety and effectiveness of cryoablation but also its capacity to yield better aesthetic results than surgical methods.

Patient Satisfaction and Cosmetic Outcomes

In the study published in the European Journal of Surgical Oncology, researchers assessed patient-reported outcomes to ascertain satisfaction with cosmetic results following the treatment. Notably, the study revealed:

• - An overall median cosmetic outcome score of 1.6 for thermal ablation, compared to 1.8 for surgery (with a P-value of 0.07).
• - High scores on the BREAST-Q instrument, which evaluates patients' quality of life and satisfaction, indicated that thermal ablation surpassed surgery in most evaluated domains.
• - An impressive 95% of participants reported being either 'very satisfied' or 'satisfied' with the thermal ablation method.
• - Furthermore, 91% of patients expressed a preference for thermal ablation over surgical alternatives.

In addition, the BCCT core method, which objectively assesses conservative breast cancer treatments, rated 94% of thermal ablation cases as good or excellent, in stark contrast to the 80% rate following surgery.

The Cryoablation Advantage

An additional article in Radiology outlined that cryoablation using ProSense® not only achieved the highest complete ablation rate without any complications but also posed fewer requirements for oncoplastic surgeries compared to radiofrequency and microwave ablation methods.

The findings are crucial for determining the preferred approaches in future trials; cryoablation has emerged as a candidate for a Phase III trial following these positive outcomes.

About ProSense®

IceCure Medical’s ProSense® system revolutionizes tumor treatment by utilizing liquid nitrogen to create vast lethal zones that can effectively destroy tumors, whether benign or malignant, across various body types including breast, kidney, lung, and liver lesions. Its minimally invasive nature significantly enhances recovery rates, reduces pain, and minimizes surgical risks—factors that both patients and healthcare providers highly value.

Conclusion

These compelling findings from the THERMAC Trial mark a significant advancement in the field of breast cancer treatment. By demonstrating the effectiveness and high patient satisfaction associated with the ProSense® system, IceCure Medical is paving the way for more inclusive and less invasive treatment options for breast cancer patients. As the company continues to develop and market its innovative cryoablation therapy systems, it remains committed to improving patient outcomes and experiences in the oncology field.